Rayca Precision

Rayca’s AI rapidly designs, screens and optimizes thousands of therapeutic candidates for hard-to-drug targets, leading our owned and partnered therapeutic pipelines from concept to IND-approval. Rayca's platform is a closed-loop process where each data point—from screening, in vitro testing, or preclinical validation—feeds back into the AI models to continuously improve future drug designs. At Rayca Precision, we decode the complexity of disease biology using advanced multi-omics analysis powered by a secured, integrated bioinformatics platform, in silico virtual screenings, and predictive modeling to accelerate drug discovery. Our platform integrates potency matrices, dynamic molecular simulations, and high-resolution structural modeling to design highly optimized drug candidates. We specialize in creating a diverse range of therapeutic modalities, including small molecules, cyclic and linear peptides, peptidomimetics, bispecific antibodies, and RNA-based drugs. Leveraging best in class algorithms, we perform large-scale virtual screenings across uncharted chemical and biomolecular spaces to uncover cryptic binding pockets and novel mechanisms of action. Rayca merges computational sophistication with iterative experimental validation. Using proprietary in silico workflows, we optimize molecular properties such as binding affinity, selectivity, and pharmacokinetics, all while minimizing off-target effects. For biologics, our epitope mapping and protein engineering pipelines refine binding interfaces to achieve superior stability and reduced immunogenicity. For small molecules and peptides, we explore chemical libraries at scale, balancing ADMET properties with therapeutic potency. From gene-editing tools to peptidomimetics, every candidate we design is rigorously tested against predictive and experimental benchmarks. Rayca delivers therapies that redefine possibilities in oncology, immunotherapy, and rare diseases.